DOI:
10.1055/s-00000094
Zeitschrift für Gastroenterologie
LinksClose Window
References
Ikeda M, Sung MW, Kudo M. et al.
A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC).
J Clin Oncol 2018;
36: 4076
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.